Market Overview

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc


Levi & Korsinsky announces it has commenced an investigation of Alkermes
plc ("Alkermes" or "the Company") (NASDAQ:ALKS) concerning possible
violations of federal securities laws.

On April 2, 2018, Alkermes announced receipt of a Refusal to File letter
from the U.S. Food and Drug Administration regarding its New Drug
Application for ALK 5461. According to Alkermes, the FDA determined it
"is unable to complete a substantive review of the regulatory package,
based on insufficient evidence of overall effectiveness for the proposed
indication, and that additional well-controlled clinical trials are
needed prior to the resubmission of the NDA for ALKS 5461." Following
this news, shares of Alkermes were down more 4% on intraday trading on
April 3, 2018. To obtain additional information, go to:

or contact Joseph E. Levi, Esq. either via email at
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York,
California, Connecticut and Washington D.C. The firm's attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior results
do not guarantee similar outcomes.

View Comments and Join the Discussion!